

Public Declaration of Interests and Confidentiality Undertaking of Swissmedic Medicines Expert Committee Members

This document is aligned to the 'Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA) Scientific Committee members and experts' of the EMA.

SECTION 1: PERSONAL DETAILS

First Name Gabriele

Last Name Thumann

Organisation / Company Hôpitaux Universitaire de Genève (HUG)

Country of Organisation /
Company Switzerland

Committee

I do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below.

Please specify the interests that you currently have (at the time of completion of the form) or have had within the past 5 years.

SECTION 2: PUBLIC DECLARATION OF INTERESTS

2.1 Employment

☒ No ☐ Yes

Please indicate if you are employed / have been employed, either full or part time, either as paid or unpaid employee in pharmaceutical company.

Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product.

2.2 Consultancy

☐ No ☒ Yes

Choose "Yes" if there is any activity in which you provide or have provided advice or services regardless as to whether or not you received a fee for this activity. Please indicate all of them below.

Provision of advice or services to a pharmaceutical company (in a particular field such as the development of a product) regardless of contractual arrangements or any form of remuneration. (Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product)

Note: Conference / Seminar attendance is not considered as consultancy but should be indicated under Financial Interests, if subject to a fee / honoraria.

Period	Company	Product	Therapeutic Indication General Role / Area of Activity	Funding
<2014	B Braun		Consultant	
<2014	Cell Cure Neurosci Ltd., Israel		Consultant	
<2014	DSM Biomedical		Consultant	

2.3 Strategic Advisory Role☒ No ☐ Yes

Choose "Yes" if you are participating or have participated in a (Scientific) Advisory Board/Steering Committee of a pharmaceutical company (e.g. board membership / directorship), with a right to vote on / influence the outcome of that body.

Participation (with a right to vote on/influence the outputs) in a (Scientific) Advisory Board/Steering Committee with the role of providing advice/expressing opinions on the (future) strategy, direction or development activities of a pharmaceutical company, either in terms of general strategy or product related strategy, regardless of contractual arrangements or any form of remuneration. Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product.

Note: Involvement in Data Safety Monitoring Committees is not included in this category. Such involvement should be recorded under section 2.6 Principal Investigator. Involvement in clinical research should be listed under section 2.6 Principal Investigator or 2.7 Investigator as appropriate.

2.4 Current Financial Interests☒ No ☐ Yes

Choose "Yes" if you have any financial interests currently held in a pharmaceutical company.

Financial interests relate to current holding of shares of a pharmaceutical company with the exclusion of independently managed investment funds/pension. Compensation, fees, honoraria, salaries currently being paid directly to you by a pharmaceutical company, other than payment for expenses incurred with research work or re-imbursement of reasonable expenses incurred in relation to conference/seminar attendance (i.e. accommodation and travel costs).

Current is interpreted at time of completion of this form.

2.5 Patent
☐ No ☒ Yes

Choose "Yes" if any patent for a medicinal / competitor product is currently owned by either yourself or your institution and you are a beneficiary.

Current is interpreted at time of completion of this form.

X

Name of Pharmaceutical Company

n.a.

Subject Matter

Pigment epithelial cell of the eye, its production and use in therapy of an eye or CNS disease

X

Name of Pharmaceutical Company

n.a.

Subject Matter

Methods and compositions for improving eye health

X

Name of Pharmaceutical Company

n.a.

Subject Matter

Methods and composition for diagnosing and treating glaucoma

2.6Principal Investigator

☐ No ☒ Yes

Choose "Yes" if there are trials for which you are acting or have acted as Principal Investigator

Principal Investigator with the responsibility for the coordination of investigators at different centres participating in a multicentre trial or the leading investigator of a monocentre trial, or the coordinating (principal) investigator signing the clinical study report. This definition does not include a national coordinating investigator in a multinational trial. Involvement in Data Safety Monitoring Committee should be included in this section.

Period	Company	Product	Therapeutic Indication General Role / Area of Activity	Funding
07/2020 - TODAY	n.a.	n.a.	Diabetic retinopathy	no
01/2023 - TODAY	n.a.	n.a.	Recognition of optic disc abnormalities using AI	no
03/<2013 - TODAY	Second Sight	Argus II	Retinal prosthesis	no
01/2023 - TODAY	n.a.	n.a.	GENE MUTATIONS IN GLAUCOMA	no

2.7 Investigator

☐ No ☒ Yes

Choose "Yes" if there are trials for which you are acting or have acted as Investigator.

Investigator involved in a clinical trial at a specific trial site who can be the responsible lead investigator of the trial at that specific site or a member of the clinical trial team who performs critical trial related procedures and makes important trial related decisions.

Period	Company	Product	Therapeutic Indication General Role / Area of Activity	Funding
03/2019 - 03/2022	Novartis	Lucentis (Ranibizumab)	AMD, macular edema, diabetic retinopathy, choroidal neovascularization	yes
10/2019 - TODAY	n.a.	n.a.	Pupil monitoring during sleep and unconsciousness	yes
07/2016 - 10/2017	n.a.	n.a.	Diabetic retinopathy	yes
12/2015 - 12/2016	Bayer	Aflibercept (Eylea)	Diabetic retinopathy, macular edema	yes
11/2015 - 11/2016	n.a.	n.a.	Uveitis	yes
06/<2013 - 11/ <2013	n.a.	n.a.	AMD	yes
11/2020 - 11/2024	n.a.	n.a.	Pathological assesement of brain and eye in stroke	no
03/2022 - TODAY	n.a.	n.a.	Establishing an evidence-based Diabetic Retinopathy Service in Timor Leste	no

2.8 Grant / Funding to organisation/institution

☐ No ☒ Yes

Choose "Yes" if any grants or other funding is currently received by your institutional unit from a pharmaceutical company and you receive no personal gain; or where your Organisation (e.g. Patient Organisation) receives a grant or other funding from a pharmaceutical company and you (irrespective if you are employed by the Organisation or are a volunteer) receive no personal gain.

Refers to a grant or other funding from a pharmaceutical company, currently being received (as far as the individual is aware) by an institution (please indicate funding to the smallest institutional unit) or an organisation (e.g. patient organisation), irrespective of whether or not the individual is employed or is a volunteer, and the individual receives no personal gain.

X

Name of Pharmaceutical Company	Böhringer-Ingelheim
Subject Matter	ex vivo model for avascular AMD
Amount of Money (CHF)	255'949
Funding paid into an institutional account with shared power of disposition?	yes

2.9 Any other interests or facts

☐ No ☒ Yes

Choose "Yes" if further to the interest declared above you have any other interests or facts that should be made known to Swissmedic, the Swiss Agency of Therapeutic Products and the public.

By choosing "No" you declare on your honour that you do not have any other interests or facts to declare accordingly.

X

Please specify

Conferences and information events for the public were sponsored by numerous (pharmaceutical) companies (details can be delivered on request). A single event was always sponsored by more than one contributor and the financial support given is in average 1'500 CHF (maximum 10'000 CHF) and conversely offers the option for a booth during the event.